Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury

Area of Science:

• Nephrology
• Molecular Biology
• Immunology

Background:

• Nuclear factor kappaB (NF-kappaB) is crucial in the development of renal ischemia-reperfusion injury (IRI).
• RelB, a component of NF-kappaB, is implicated in IRI pathogenesis.
• Small interfering RNA (siRNA) offers a potential therapeutic strategy to target RelB in renal IRI.

Purpose of the Study:

• To investigate the protective effects of RelB-targeting siRNA against renal IRI in a mouse model.
• To evaluate the impact of siRNA-mediated RelB silencing on renal function, histology, and survival.

Main Methods:

• Renal IRI was induced in mice by clamping the renal pedicle.
• Therapeutic efficacy of RelB siRNA was assessed by measuring renal function (blood urea nitrogen, serum creatinine), histological damage, and overall survival.
• Tumor necrosis factor-alpha expression was evaluated using immunohistochemistry.

Main Results:

• A single injection of RelB siRNA effectively reduced renal RelB expression.
• siRNA treatment significantly decreased blood urea nitrogen and serum creatinine levels compared to controls.
• Histological examination showed marked reduction in IRI-induced tissue injury and attenuated tumor necrosis factor-alpha expression.
• RelB siRNA pretreatment resulted in an 80% survival rate in mice subjected to lethal IRI, compared to over 90% mortality in control mice.

Conclusions:

• Silencing RelB expression using siRNA significantly mitigates IRI-induced renal dysfunction and injury.
• siRNA-based therapy targeting RelB demonstrates substantial protective effects against lethal kidney ischemia in mice.
• These findings highlight the potential of siRNA as a clinical therapeutic strategy for renal IRI.